Minimal Residual Disease
VIDEO: Use of circulating tumor DNA as minimal residual disease in colorectal cancer
In this video, Arvind Dasari, MD, MS, discussed data from multiple ASCO Gastrointestinal Cancers Symposium presentations highlighting the use of ctDNA as a minimal residual disease in colorectal cancer.
VIDEO: Trial builds on current microsatellite instability-high colorectal cancer therapy
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma
SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.
Terminated study’s ‘challenges’ may guide future trials of MRD-guided breast cancer therapy
SAN ANTONIO — A randomized phase 3 clinical trial designed to assess whether circulating tumor DNA surveillance could be used to help prevent breast cancer recurrence closed early due to a lack of patients eligible for randomization.
“Back to the Future”: Developments in Immunotherapy with David Gandara, MD
In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more.
Consolidative HSCT may not be necessary for some patients with mantle cell lymphoma
SAN DIEGO — Autologous hematopoietic stem cell transplantation did not benefit adults with mantle cell lymphoma in first complete remission after induction, according to randomized phase 3 data presented at ASH Annual Meeting and Exposition.
VIDEO: Utilizing minimal residual disease testing in acute lymphoblastic leukemia
Healio spoke with John Molina, MD, MEd, about research on the use of minimal residual disease testing in acute lymphoblastic leukemia presented at Society of Hematologic Oncology Annual Meeting.
Maintenance combination extends PFS in newly diagnosed multiple myeloma
The addition of daratumumab to maintenance lenalidomide extended PFS for patients who underwent stem cell transplant for newly diagnosed multiple myeloma, according to study results.
Measurable residual disease status predicts PFS for patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia who achieved undetectable minimal residual disease achieved significantly longer PFS than patients with minimal residual disease, according to results of a systematic review and meta-analysis.
VIDEO: MRD testing a hot topic in multiple myeloma
CHICAGO — In this video, Sandra Mazzoni, DO, discusses the use of minimal residual disease, or MRD, testing in multiple myeloma.